Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management.

ABSTRACT: The unprecedented progress in addressing unmet needs in haemophilia care to date includes developing several novel therapies that rebalance haemostasis by restoring thrombin generation in patients with haemophilia A or B with and without inhibitors. These novel therapies are FVIII mimetics, antithrombin interference RNA therapy and several monoclonal antibodies directed against the tissue factor pathway inhibitor (anti-TFPI). In this review, we provide an update on the progress made in developing anti-TFPI therapie. Phase 1 data from the three anti-TFPI studies showed acceptable safety profiles, and currently, available phase 2 data are encouraging. While these data support these molecules' further development progression, there is uncertainty on several aspects of their evolution. Two of

SUBMITTER: Mahlangu JN 

PROVIDER: S-EPMC8131856 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature